The offer was just for testing... I guess this was
Post# of 148279
(Total Views: 581)
Posted On: 08/28/2020 10:12:04 AM
The offer was just for testing... I guess this was a first step to at least make the MIS-C to RANTES connection.
"Cytodyn... today announced it is offering comprehensive cytokine profiling (including RANTES levels) through its diagnostic partner company, IncellDx, to help physicians understand the pathogenesis of Childhood Inflammatory Disease Related to COVID-19. These laboratory tests are exploratory in nature and not intended for clinical decision making."
I bring this up because MESO was able to save a 4 yr old patient who had MIS-C brought upon by COVID and am certain Leronlimab can help too. MESO just received 9-1 vote in favor of FDA approval for a single arm study because it involved child mortality. All the forces working against Leronlimab could be negated when going against health & safety of children. From a purely strategic standpoint, this would have been the most sure thing on the path to approval IMO.
https://web.musc.edu/about/news-center/2020/0...s-hospital
"Cytodyn... today announced it is offering comprehensive cytokine profiling (including RANTES levels) through its diagnostic partner company, IncellDx, to help physicians understand the pathogenesis of Childhood Inflammatory Disease Related to COVID-19. These laboratory tests are exploratory in nature and not intended for clinical decision making."
I bring this up because MESO was able to save a 4 yr old patient who had MIS-C brought upon by COVID and am certain Leronlimab can help too. MESO just received 9-1 vote in favor of FDA approval for a single arm study because it involved child mortality. All the forces working against Leronlimab could be negated when going against health & safety of children. From a purely strategic standpoint, this would have been the most sure thing on the path to approval IMO.
https://web.musc.edu/about/news-center/2020/0...s-hospital
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼